Citius Pharmaceuticals, Inc. (CTXR) Fair Value 2026

CTXR · Pharmaceutical Preparations ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

3.3 /10

32 fundamental signals · 5 models active

Value Trap Risk

LOW (36/100)

Quick Summary — As of 2026-07-15, Citius Pharmaceuticals, Inc. (CTXR) trades at $0.53. QOC: 3.3/10. Value Trap Risk: 36/100 (LOW). 5/13 models active.

Key Facts

Ticker
CTXR
Price
$0.53
Quality Score
3.3/10
Value Trap Risk
36/100
Models Active
5/13
Last Updated
Strength: 5 independent models provide multi-angle coverage
Risk: Below-average Quality Score of 3.3/10 signals weak fundamentals

Is Citius Pharmaceuticals, Inc. (CTXR) Undervalued or Overvalued in 2026?

According to CirclFi’s 5-model valuation engine, Citius Pharmaceuticals, Inc. (CTXR) appears overvalued as of : the median of 5 independent fair value estimates is $0.33, 38.5% below the current price of $0.53. Estimates range from $0.01 to $2.33. CTXR scores 3.3/10 on fundamental quality and 36/100 on value-trap risk.

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Citius Pharmaceuticals, Inc. Stock in 2026? →

Valuation Matrix

5 Intrinsic Value Models vs. Current Price ($0.53)

Core Models (Unlocked)
Model Fair Value Upside
CUCE Ensemble
Low Conviction
 $0.47 -12.3%
ML-RIV
High Conviction
 $0.33 -38.5%

Unlock the Full Matrix

Access 3 additional models including Dynamic NAV, Regime Cross-Sectional, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 5 Models →

Cancel anytime · No contracts · Instant access

What Is Citius Pharmaceuticals, Inc. (CTXR) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Citius Pharmaceuticals, Inc.'s intrinsic value is estimated at $0.64, suggesting the stock is overvalued at its current price of $0.53. With 4 out of 5 models flagging downside (+21.1% average return), the market may be pricing in unsustainable growth. The most optimistic model, FTNN, places fair value at $2.33 (+338.3%), while Regime Cross — the most conservative — estimates $0.01 (-98.1%). This +436.4% gap reflects genuine analytical uncertainty about Citius Pharmaceuticals, Inc.'s intrinsic worth.

What Do the Models Say About CTXR?

5 of 13 models are currently active for CTXR. Of these, 1 model suggests upside while 4 models suggest overvaluation. See which stocks rank higher →

How Does CTXR Rank in Pharmaceutical Preparations?

Among 431 Pharmaceutical Preparations stocks, CTXR ranks #381 by Quality of Company score. CirclFi's QOC score of 3.3/10 evaluates 32 fundamental signals. A score of 3.3 signals below-average fundamentals.

See all Most Undervalued Pharmaceutical Preparations Stocks →

As a pharmaceutical industry, Citius Pharmaceuticals, Inc. operates in a sector where revenue per drug is a critical driver of valuation. Investors evaluating CTXR should weigh these sector-specific dynamics alongside our model-derived fair values.

Is CTXR a Value Trap?

CirclFi's Value Trap algorithm assigns CTXR a score of 36/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

5 of 13 models are active for Citius Pharmaceuticals, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Citius Pharmaceuticals, Inc.'s fundamental quality profile registers 3.3/10. This concerning score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

The gap between the most bullish and bearish model spans +436.4% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every CTXR valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across CTXR's 5 active models, average confidence is 26%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Citius Pharmaceuticals, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Pharmaceutical Preparations Stocks Should You Also Analyze?

8 related Pharmaceutical Preparations stocks with 13-model coverage

AZNAstraZeneca PLCQOC 10.0CPRXCatalyst Pharmaceuticals, Inc.QOC 10.0HRMYHarmony Biosciences Holdings, IQOC 10.0NVONovo Nordisk A/SQOC 10.0SIGASIGA Technologies Inc.QOC 10.0UTHRUnited Therapeutics CorporationQOC 10.0ZTSZoetis Inc.QOC 10.0RDYDr. Reddy's Laboratories LtdQOC 9.9

Read investment analysis: AZN · CPRX · HRMY · NVO · SIGA

See all Pharmaceutical Preparations stocks ranked →

Frequently Asked Questions About Citius Pharmaceuticals, Inc.

What is Citius Pharmaceuticals, Inc.'s intrinsic value in 2026?

Based on CirclFi's 13-model analysis, Citius Pharmaceuticals, Inc. (CTXR) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value. The Quality of Company score is 3.3/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is CTXR overvalued or undervalued right now?

At $0.53, 1 of 5 active models suggest CTXR may be undervalued, while 4 indicate potential overvaluation. The median of all 5 fair value estimates is $0.33, 38.5% below the current price of $0.53 — a consensus view that CTXR is overvalued. The assessment depends on which methodology best fits Citius Pharmaceuticals, Inc.'s business model in Pharmaceutical Preparations.

What does a Quality of Company score of 3.3 mean for CTXR?

Citius Pharmaceuticals, Inc.'s QOC of 3.3/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on CTXR?

CirclFi analyzes CTXR with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 5 of 13 are active for this stock. Read the full methodology →

Is CTXR a value trap in 2026?

Citius Pharmaceuticals, Inc.'s Value Trap score is 36/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 5-model valuation engine, Citius Pharmaceuticals, Inc. (CTXR) has a median fair value of $0.33 — 38.5% below the current price of $0.53 — as of 2026-07-15.” Source: circlfi.com/stock/CTXR/ · Methodology

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 5 mathematical frameworks give you clarity on CTXR.

Unlock All 5 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access